Skip to main content

Table 1 Demographic data, lipid pathway-based genotypes, cerebrospinal fluid biomarkers, and global cognitive performance across the AD spectrum

From: Dyslipidemia induced large-scale network connectivity abnormality facilitates cognitive decline in the Alzheimer’s disease

Items

CN

EMCI

LMCI

AD

P values

(n = 51)

(n = 26)

(n = 26)

(n = 21)

 Age (years)

74.08 ± 5.79

70.04 ± 6.87

70.81 ± 7.14

71.81 ± 7.77

0.051

 Gender (F/M)

30/21

14/12

11/15

9/12

0.447*

 Education (years)

16.31 ± 2.59

15.27 ± 2.51

16.31 ± 2.51

15.14 ± 2.76

0.157

Multiple protective genes

 CLU T status (TC + TT/CC)

38/13

17/9

18/8

13/8

0.710*

 LDLR A status (AG + AA/GG)

38/13

16/10

15/11

11/10

0.240*

 LRP1 T status (TC + TT/CC)

15/36

8/18

5/21

10/11

0.214*

 PICALM A status (AG + AA/GG)

27/24

15/11

16/10

11/10

0.884*

Multiple risk genes

 APOE ε4 status (+ / −)

15/36

14/12

12/14

15/6

0.008*

 SORL1 G status (TG + GG/TT)

19/32

12/14

12/14

6/15

0.548*

 CETP A status (AG + AA/GG)

46/5

24/2

23/3

19/2

0.974*

 ABCA1 G status (AG + GG/AA)

45/6

25/1

21/5

19/2

0.369*

 BIN1 C status (TC + CC/TT)

27/24

17/9

15/11

11/10

0.739*

Cerebrospinal fluid biomarkers

 Aβ (pg/ml)

192.79 ± 50.17bc

183.61 ± 50.66d

168.77 ± 50.80

140.40 ± 43.59

0.001

 Tau (pg/ml)

68.53 ± 34.14c

79.32 ± 51.89d

86.01 ± 52.19e

129.29 ± 61.42

 < 0.001

 pTau (pg/ml)

34.18 ± 16.58bc

39.60 ± 24.73d

48.42 ± 33.50

55.23 ± 26.13

0.005

Global cognitive performance

 MMSE

28.84 ± 1.16abc

27.92 ± 2.13d

27.73 ± 1.54e

22.67 ± 2.50

 < 0.001

 ADAS-Cog

10.76 ± 6.53abc

14.19 ± 6.58d

16.96 ± 5.32e

35.81 ± 8.99

 < 0.001

  1. *, p values were obtained using a Chi-square test; other p values were obtained from a one-way ANOVA. Unless indicated, data are presented as means ± standard deviation. Post hoc analyses were used with least significance difference correction (p < 0.05): a: statistical difference detected between CN group and EMCI group; b: statistical difference was detected between CN group and LMCI group; c: statistical difference was detected between CN group and AD group; d: statistical difference was detected between EMCI group and AD group; e: statistical difference was detected between LMCI group and AD group. CN cognitively normal, EMCI early mild cognitive impairment, LMCI late mild cognitive impairment, AD Alzheimer’s disease, M/F male/female, CLU clusterin, LDLR low density lipoprotein receptor, LRP1 low density lipoprotein receptor-related protein 1, PICALM phosphatidylinositol-binding clathrin assembly protein, APOE apolipoprotein E, SORL1 sortilin-related receptor 1, CETP cholesterol ester transfer protein, ABCA1 ATP-binding cassette transporter A1; BIN1 bridging integrator 1, amyloid-1 to 42 peptide, Tau total tau, pTau tau phosphorylated at the threonine 181 position, MMSE mini-mental state examination, ADAS-Cog Alzheimer’s Disease Assessment Scale-Cognitive Subscale